Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  SAP SE    SAP   DE0007164600


Real-time Estimate Quote. Real-time Estimate Tradegate - 01/21 01:04:00 pm
104.87 EUR   +0.01%
08:52aSAP : to Release Fourth Quarter and Year-End 2020 Results
01:54aSAP SE : UBS remains Neutral
01/20ANALYSIS : Europe Inc earnings in no man's land between recession and recovery
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SAP : New Blockchain Software from SAP Helps Eliminate Counterfeit Drugs

01/16/2019 | 09:39am EST

WALLDORF - SAP SE (NYSE: SAP) today announced the general availability of SAP Information Collaboration Hub for Life Sciences, option for U.S. supply chain, a blockchain-technology hub to help eliminate counterfeit products along the pharmaceutical supply chain.

The hub is designed to authenticate pharmaceutical packaging returned from hospitals and pharmacies to wholesalers before products are resold. U.S. wholesalers encounter nearly 60 million returns annually, accounting for an estimated US$7 billion.

The blockchain-based solution helps customers comply with the U.S. Drug Supply Chain Security Act (DSCSA), which requires that as of November 2019 wholesalers verify prescription drugs that are returned and intended for resale. The mandate is intended to protect consumers from fake, contaminated and stolen medication.

'Blockchain is driving a new breed of enterprise applications that could drastically improve cooperation for wholesale distribution,' said Jeffery Denton, senior director, Global Secure Supply Chain, AmerisourceBergen Corporation. 'The blockchain-based solution from SAP provides the best opportunity to fully satisfy our need to be interoperable with our trading partners and their solutions as well as to remain compliant with the U.S. DSCSA.'

The new software allows customers to verify the product code, lot, expiration date and a unique serial number embedded in the barcode against manufacturers' data stored in the blockchain. The software was developed in co-innovation with AmerisourceBergen, Boehringer Ingelheim AG & Co. KG, GlaxoSmithKline plc and Merck Sharp & Dohme, among others.

'This blockchain product supports the industry's need for an immutable and shared ledger, avoiding many complex integrations,' said Dr. Oliver Nuernberg, chief product owner, SAP for Life Sciences solution portfolio, SAP SE. 'With this product we are offering a scalable and secure solution to pharmaceutical manufacturers and U.S. wholesalers to comply with the upcoming regulatory requirements for verification.'

SAP continues to support companies across various industries in exploring the benefits of the distributed ledger technology. In autumn 2018, two new industry consortia within the SAP Blockchain Consortium program were announced. The addition of these new consortia serves as proof of SAP's ongoing efforts to provide the right platform, framework and organization for customers exploring the adoption and integration of blockchain technology for enterprise applications.

Visit the SAP News Center. Follow SAP on Twitter at @sapnews.

Media Contacts:
Ilaina Jonas, +1 (646) 495-6643, ilaina.jonas@sap.com, ET
Benjamin Nickel, +49 331 97995-376, benjamin.nickel@sap.com, CET
SAP News Center press room; press@sap.com

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP's future financial results are discussed more fully in SAP's filings with the U.S. Securities and Exchange Commission ('SEC'), including SAP's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
© 2019 SAP SE. All rights reserved.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices.


SAP SE published this content on 16 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 16 January 2019 14:38:02 UTC

© Publicnow 2019
All news about SAP SE
08:52aSAP : to Release Fourth Quarter and Year-End 2020 Results
01:54aSAP SE : UBS remains Neutral
01/20ANALYSIS : Europe Inc earnings in no man's land between recession and recovery
01/20SAP : CEIPAL's AI-Powered Recruitment & Talent Management Platform Now Available..
01/19SAP : Preferred Success Reveals the Cloud's Influence on Customer Experience
01/19SAP's Qualtrics Looks to Raise More Than $1 Billion in IPO
01/18SAP : Top Five Reasons to Enter the SAP Innovation Awards
01/18SAP : Preferred Success Opens the Door to Talent Businesses Need Now
01/18SAP SE : Independant Research maintains a Buy rating
01/15GLOBAL MARKETS LIVE: Citigroup, Wells Fargo, SAP…
More news
Sales 2020 27 280 M 33 170 M 33 170 M
Net income 2020 4 742 M 5 766 M 5 766 M
Net Debt 2020 8 826 M 10 732 M 10 732 M
P/E ratio 2020 25,9x
Yield 2020 1,58%
Capitalization 125 B 151 B 152 B
EV / Sales 2020 4,90x
EV / Sales 2021 4,80x
Nbr of Employees 101 450
Free-Float 86,2%
Chart SAP SE
Duration : Period :
SAP SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAP SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 117,22 €
Last Close Price 104,86 €
Spread / Highest target 38,3%
Spread / Average Target 11,8%
Spread / Lowest Target -32,3%
EPS Revisions
Managers and Directors
Christian Klein Co-Chief Executive Officer & COO
Hasso Plattner Chairman-Supervisory Board
Luka Mucic Chief Financial Officer
Juergen Mueller Chief Technology Officer
Lars Lamadé Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
SAP SE-2.20%151 064
INTUIT INC.2.53%107 509
SERVICENOW INC.-1.50%105 754
DOCUSIGN, INC.14.85%47 630
RINGCENTRAL, INC.-0.23%33 891